Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Major Depressive Disorder Market?

The market size for major depressive disorder has experienced a consistent rise in the past few years. It is projected to expand from $6.12 billion in 2024 to $6.28 billion in 2025, with a compound annual growth rate (CAGR) of 2.6%. Progress in pharmaceuticals, increased consciousness about mental health, psychological therapies, and public health campaigns have all contributed to the growth during the historic period.

What Growth Rate Is Forecasted for the Major Depressive Disorder Market by 2029?

Anticipated to witness a steady rise in the coming years, the market size for major depressive disorder is set to escalate to a valuation of $7.13 billion by 2029, growing at a compound annual growth rate (CAGR) of 3.2%. This growth during the forecast period is largely attributable to advancements in precision medicine, the rise of telepsychiatry and teletherapy, introduction of innovative treatment methodologies, and the global proliferation of mental health services. The forecast period will also see major developments such as early intervention techniques, increased peer support and creation of online communities, adoption of holistic treatment measures as well as resilience and coping strategies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

Which Key Companies Are Shaping the Future of the Major Depressive Disorder Market?

Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research And Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co.Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon PLC, Allergan PLC, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BioLite Inc., BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Arrivo Bioventures LLC, Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

Which Factors Are Driving Demand in the Major Depressive Disorder Industry?

A surge in substance misuse and alcoholism is anticipated to stimulate the expansion of the major depressive disorder market. The terms substance and alcohol abuse refer to behaviours marked by excessive and detrimental consumption of substances, including alcohol, which can culminate in harmful physical, psychological, and social effects. These misuses and major depressive disorder often coexist, mutually fueling each other and raising the possibility of physical and mental damage. For example, a 2024 survey by the Substance Abuse and Mental Health Services Administration, a US health and human services department, reported that 3.1% of people, or 8.9 million, misused opioids in 2023, while 21.8% of individuals over 12 years old used marijuana, the most widely used illicit drug. Additionally, nicotine vaping was reported in the past month by 9.4% of people aged 12 and over, a rise from 8.3% in 2022. Consequently, increased substance and alcohol abuse is fuelling the growth of the major depressive disorder market. The major depressive disorder market is also powered by a spike in anxiety cases. Anxiety, a standard response to stressful situations that evokes sensations of fear, overwhelming apprehension, and unease, provokes intense, excessive, and prolonged worry over regular events. Anxiety’s striking impact on major depressive disorder stems from symptoms such as restlessness, irritability, and difficulties in sleeping or focusing. For example, the American Psychiatric Association, a US-based non-profit organization, stated in May 2024 that 43% of adults reported being more anxious than the year before, up from 37% in 2023 and 32% in 2022. Therefore, the upsurge in anxiety cases is pushing the growth of the major depressive disorder market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13042&type=smp

How Is the Major Depressive Disorder Market Segmented by Several Divisions?

The major depressive disorder market covered in this report is segmented –

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments

2) By Diagnosis: Physical Examinations, Laboratory Tests, Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5), Other Diagnosis

3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:

1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy

2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants

3) Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT

4) Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)

5) Other: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

What are the Emerging Market Trends Driving the Growth of the Major Depressive Disorder Industry?

Major depressive disorder market’s key players primarily concentrate on fostering product innovation and securing necessary approvals to establish a competitive edge. The quantity of drug approvals for treating major depressive disorders, such as VRAYLAR (cariprazine), is rising, underscoring the demand for safer, more potent treatments. For example, AbbVie Inc., a pharmaceutical firm based in the US, obtained FDA’s approval in December 2022 for using VRAYLAR (cariprazine) in combination with antidepressants to treat adults suffering from a major depressive disorder (MDD). VRAYLAR represents an innovative approach in atypical antipsychotic medications, as it regulates the balance of dopamine and serotonin in the brain. It is the first medication of its kind to be approved for adjunctive use in major depressive disorder treatment. It’s also available in a daily capsule.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Which Regions Are Driving Growth in the Major Depressive Disorder Market?

North America was the largest region in the major depressive disorder market in 2024. The regions covered in major depressive disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13042

This Report Delivers Insight On:

1. How big is the major depressive disorder market, and how is it changing globally?

2. Who are the major companies in the major depressive disorder market, and how are they performing?

3. What are the key opportunities and risks in the major depressive disorder market right now?

4. Which products or customer segments are growing the most in the major depressive disorder market?

5. What factors are helping or slowing down the growth of the major depressive disorder market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model